Imunoterapia e nanotecnologia: associação promissora no tratamento de neoplasias
DOI:
10.24281/rremecs2024.9.15.156167Palavras-chave:
Nanomedicina, Imunoterapia, Terapêutica, NeoplasiasResumo
O câncer, doença multifatorial, geralmente é tratado principalmente com quimioterapia, a qual pode apresentar como limitações efeitos colaterais e resistência de alguns tipos de tumores, levando à necessidade do surgimento de alternativas inovadoras. Assim, esse trabalho tem como objetivo principal compreender a terapia combinada de imunoterapia e nanotecnologia no tratamento de neoplasias. O estudo foi realizado através de uma revisão integrativa de manuscritos selecionados na plataforma de dados PubMed, utilizando os descritores “Nanomedicine”, “Immunotherapy”, “Therapeutics” e “Neoplasms”, combinados em uma única estratégia de busca utilizando o operador booleano “AND”. Foram incluídos trabalhos publicados de 2019 a 2023, disponibilizados gratuitamente e que contemplassem o tratamento combinado, resultando em dezenove artigos para compor esta revisão. Sendo discutidos biomarcadores, nanofármacos, vacinas e nanocarregadores. A terapia combinada emerge como abordagem terapêutica de sucesso. Contudo, há dificuldade de produção em massa, faltam métodos analíticos precisos e equipamentos, sendo necessário mais trabalhos a respeito.
Descritores: Nanomedicina, Imunoterapia, Terapêutica, Neoplasias.
Immunotherapy and nanotechnology: a promising combination in the treatment of neoplasms
Abstract: Cancer, a multifactorial disease, is usually treated mainly with chemotherapy, which can present side effects and resistance in some types of tumors, leading to the need for innovative alternatives. Thus, the main objective of this study is to understand the combined therapy of immunotherapy and nanotechnology in the treatment of neoplasms. The study was carried out through an integrative review of selected manuscripts on the PubMed data platform, using the descriptors "Nanomedicine", "Immunotherapy", "Therapeutics" and "Neoplasms", combined in a single search strategy using the Boolean operator "AND". We included papers published between 2019 and 2023, freely available and covering combined treatment, resulting in nineteen articles to make up this review. Biomarkers, nanopharmaceuticals, vaccines and nanocarriers were discussed. Combination therapy is emerging as a successful therapeutic approach. However, mass production is difficult, precise analytical methods and equipment are lacking, and more work is needed on this subject.
Descriptors: Nanomedicine, Immunotherapy, Therapeutics, Neoplasms.
Inmunoterapia y nanotecnología: asociación prometedora en el tratamiento de neoplasias
Resumen: El cáncer, una enfermedad multifactorial, suele tratarse principalmente con quimioterapia, que puede presentar efectos secundarios y resistencia en algunos tipos de tumores, lo que lleva a la necesidad de buscar alternativas innovadoras. El objetivo principal de este estudio es, por tanto, conocer la terapia combinada de inmunoterapia y nanotecnología en el tratamiento de neoplasias. El estudio se realizó mediante una revisión integradora de manuscritos seleccionados en la plataforma de datos PubMed, utilizando los descriptores "Nanomedicine", "Immunotherapy", "Therapeutics" y "Neoplasms", combinados en una única estrategia de búsqueda mediante el operador booleano "AND". Se incluyeron trabajos publicados entre 2019 y 2023, de libre acceso y que cubrieran tratamientos combinados, resultando diecinueve artículos para conformar esta revisión. Se analizaron biomarcadores, nanofármacos, vacunas y nanotransportadores. La terapia combinada se perfila como un enfoque terapéutico de éxito. Sin embargo, la producción masiva es difícil, faltan métodos analíticos y equipos precisos, y es necesario seguir trabajando sobre este tema.
Descriptores: Nanomedicina, Inmunoterapia, Terapéutica, Neoplasias.
Referências
Instituto Nacional do Câncer. O que é câncer? Rio de Janeiro. 2022. Disponível em: <https://www.gov.br/inca/pt-br/assuntos/cancer/o-que-e-cancer>.
Santos M, et al. Estimativa de incidência de câncer no Brasil: 2023-2025. Rev Bras Cancerologia. 2023; 69.
Rodrigues POP, Claudiano ARF, Araújo EPQ. Nanotecnologia aplicada ao tratamento do Câncer. Observatorio de la Economía Latinoamericana. 2023; 21:10501-10513.
Ferreira MCM, et al. Detecção precoce e prevenção do câncer do colo do útero: conhecimentos, atitudes e práticas de profissionais da ESF. Ciência & Saúde Coletiva. 2020; 27:2291-2302.
Júnior ATF, et al. Imunoterapia: uma revisão sobre os novos horizontes no combate ao câncer. Rev Medicina. 2020; 99:148-155.
Shi Y, Lammers T. Combining nanomedicine and immunotherapy. Accounts of Chemical Research. 2019; 52:1543-1554.
Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nature Reviews Immunology. 2020; 20:321-334.
Zhang Y, et al. Nanovaccines for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2019; 11:1559.
Wei G, et al. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021; 11.
Lecocq Q, et al. Theranostics in immuno-oncology using nanobody derivatives. Theranostics. 2019; 9:7772.
Shi Y, et al. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020; 10(17).
Aikins ME, Xu C, Moon JJ. Engineered nanoparticles for cancer vaccination and immunotherapy. Accounts of chemical research. 2020; 53(10):2094-2105.
Hagan IVCT, et al. Enhancing combined immunotherapy and radiotherapy through nanomedicine. Bioconjugate Chemistry. 2020; 31:2668-2678.
Sun Q, et al. Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacologica Sinica. 2020; 41:954-958.
Lin YX, et al. RNA nanotechnology-mediated cancer immunotherapy. Theranostics. 2020; 10(1):281.
Van Herk S, De Geest BG. Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics. Acta Pharmacologica Sinica. 2020; 41:881-894.
Kim SS, et al. A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma. International Journal of Cancer. 2019; 145:2535-2546.
Saeed M, et al. Engineering nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy. Theranostics. 2019; 9:7981-8000.
Song Q, et al. Applications of magnetite nanoparticles in cancer immunotherapies: present hallmarks and future perspectives. Frontiers in Immunology. 2021; 12.
Soetaert F, et al. Cancer therapy with iron oxide nanoparticles: agents of thermal and immune therapies. Advanced Drug Delivery Reviews. 2020; 163:65-83.
Kim SS, et al. A novel P53 nanomedicine reduces immunosuppression and augments anti-PD-1 therapy for non-small cell lung cancer in syngeneic mouse models. Cells. 2022; 11:3434.
Sofias AM, et al. A paradigm shift in cancer nanomedicine: From traditional tumor targeting to leveraging the immune system. Drug Discovery Today. 2021; 26:1482-1489.
Liu X, et al. Development of facile and versatile platinum drug delivering silicasome nanocarriers for efficient pancreatic cancer chemo‐immunotherapy. Small. 2021; 17:2005993.
Lee NK, et al. Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer. Biomaterials. 2021; 277:121105.
Publicado
- Visualizações 0
- pdf downloads: 0
Como Citar
Edição
Seção
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.